Sensitivity pattern of gram negative bacilli to three β-lactam/β- lactamase inhibitor combinations using the automated API system

Indian Journal of Medical Microbiology

Volumn 25, Issue 3, 2007, Pages 203-208

  Anuradha, K ^a   Sailaja, V ^a   Umabala, P ^a   Satheesh, T ^a   Lakshmi, V ^a  

^a NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

API; Gram negative bacteria; Sensitivity; lactamase inhibitors

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFEPIME; CEFPIROME; CEFTAZIDIME; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; TIMENTIN;

ANTIBIOTIC RESISTANCE; ARTICLE; AUTOMATION; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; LABORATORY; NONHUMAN; PSEUDOMONAS AERUGINOSA;

EID: 34848841000     PISSN: 02550857     EISSN: 02550857     Source Type: Journal    
DOI: 10.4103/0255-0857.34759     Document Type: Article

References (17)

1. Maiti SN, Phillips OA, Micetich RG, Livermore DM. Beta-lactamase inhibitors: Agents to overcome bacterial resistance. Curr Med Chem 1998;5:441-56.
2. Williams JD. Beta-lactamases and Beta-lactamase inhibitors. Int J Antimicrob Agents 1999;12:S3-7.
3. Kotra LP, Mobashery S. Mechanistic and clinical aspects of beta-lactam antibiotics and Beta-lactamases. Arch Immunol Ther Exp (Warsz) 1999;47:211-6.
4. Rotschafer JC, Ostergaard BE. Combination beta-lactam and beta-lactamase-inhibitor products: Antimicrobial activity and efficiency of enzyme inhibition. Am J Health Syst Pharm 1995;52:S15-22.
5. Lee N, Yuen KY, Kumana CR. Clinical role of beta-lactam/ beta-lactamase inhibitor combinations. Drugs 2003;63:1511-24.
6. Sandanayaka VP, Prashad AS. Resistance to beta-lactam antibiotics: Structure and mechanism based design of beta-lactamase inhibitors. Curr Med Chem 2002;9:1145-65
7. Miller LA, Ratnam K, Payne DJ. Beta-lactamase-inhibitor Combinations in the 21st century: Current agents and new developments. Curr Opin Pharmacol 2001;1:451-8.
8. de la Pena A, Derendorf H. Pharmacokinetic properties of beta-lactamase inhibitors. Int J Clin Pharmacol Ther 1999;37:63-75.
9. Lister PD. Beta-lactamase inhibitor combinations with extended-spectrum penicillins: Factors influencing antibacterial activity against Enterobacteriaceae and Pseudomonas aeruginosa. Pharmacotherapy 2000;20:213S-8S.
10. Niki Y. Fundamental and clinical studies on beta-lactamase inhibitors. Nippon Rinsho 2001;59:771-6.
11. Sader HS, Tosin I, Sejas L, Miranda E. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: Piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam. Braz J Infect Dis 2000;4:22-8.
12. Baron EJ, Jones RN. National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centers. Diagn Microbiol Infect Dis 1995;21:141-51.
13. Bonfiglio G, Laksai Y, Franceschini N, Perilli M, Segatore B, Bianc Stefani S, et al. In vitro activity of piperacillin-tazobactam against 615 Pseudomonas aeruginosa strains isolated in intensive care units. Chemotherapy 1998;44:305-12.
14. Gobernado M, Bouza E, Perea E, Alvarez-Bravo J, García Rodríguez JA. A national Multicenter study of the in-vitro activity of piperacillin-tazobactam. The Spanish piperacillin-tazobactam group. Rev Esp Quimioter 1998;11:139-46.
15. Blahova J, Hupkova M, Kremery V Sr. The effectiveness of so-called potentiated penicillins (augmentin and tazobactam) in vitro. Cas Lek Cesk 1995;134:558-61.
16. Suh B, Shapiro T, Jones R, Satishchandran V, Truant AL. In vitro activity of beta-lactamase inhibitors against clinical isolates of Acinetobacter species. Diagn Microbiol Infect Dis 1995;21:111-4.
17. Hart SM, Bailey EM. A practical look at the clinical usefulness of the beta-lactam/beta-lactamase inhibitor combinations. Ann Pharmacother 1996;30:1130-40.